PMID- 37484969
OWN - NLM
STAT- MEDLINE
DCOM- 20230725
LR  - 20230725
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - New potential biomarkers for early chronic kidney disease diagnosis in patients 
      with different glucose tolerance status.
PG  - 1206336
LID - 10.3389/fendo.2023.1206336 [doi]
LID - 1206336
AB  - BACKGROUND: The purpose of the present study was to investigate the role of 
      oxidative stress, platelet activation, and endocan levels in renal dysfunction in 
      normal glucose tolerance (NGT) patients with 1-h plasma glucose values >/=155 mg/dl 
      (NGT >/= 155), compared to NGT < 155, impaired glucose tolerance (IGT), and type 2 
      diabetes mellitus (T2DM) newly diagnosed subjects. We enlisted 233 patients 
      subjected to an oral glucose tolerance test (OGTT). MATERIALS AND METHODS: The 
      serum levels of platelet activation (glycoprotein VI and sP-selectin), oxidative 
      stress biomarkers (8-isoprostane and Nox-2), and endocan were evaluated using an 
      ELISA test. RESULTS: Among NGT < 155 patients and the T2DM group, there was a 
      statistically significant increase in 8-isoprostane (p < 0.0001), Nox-2 (p < 
      0.0001), glycoprotein VI (p < 0.0001), and sP-selectin (p < 0.0001) serum levels. 
      Higher serum endocan levels were found with the worsening of metabolic profile (p 
      < 0.0001); specifically, NGT >/= 155 patients presented higher serum endocan values 
      when compared to NGT < 155 patients (p < 0.0001). From the multivariate linear 
      regression analysis, 1-h glucose resulted in the major predictor of estimated 
      glomerular filtration rate (e-GFR) justifying 23.6% of its variation (p < 
      0.0001); 8-isoprostane and Nox-2 added respectively another 6.0% (p < 0.0001) and 
      3.2% (p = 0.001). CONCLUSION: Our study confirmed the link between 1-h post-load 
      glucose >/=155 mg/dl during OGTT and the possible increased risk for chronic kidney 
      disease (CKD) in newly diagnosed patients. The novelty is that we demonstrated a 
      progressive increase in oxidative stress, platelet activation, and serum endocan 
      levels with the worsening of metabolic profile, which becomes evident early 
      during the progression of CKD.
CI  - Copyright (c) 2023 Cassano, Pelaia, Armentaro, Miceli, Tallarico, Perini, 
      Fiorentino, Imbalzano, Maio, Succurro, Hribal, Andreozzi, Sesti and Sciacqua.
FAU - Cassano, Velia
AU  - Cassano V
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Pelaia, Corrado
AU  - Pelaia C
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Armentaro, Giuseppe
AU  - Armentaro G
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Miceli, Sofia
AU  - Miceli S
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Tallarico, Valeria
AU  - Tallarico V
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Perini, Daniele Dallimonti
AU  - Perini DD
AD  - Department of Experimental and Clinical Medicine, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Fiorentino, Vanessa T
AU  - Fiorentino VT
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Imbalzano, Egidio
AU  - Imbalzano E
AD  - Department of Clinical and Experimental Medicine, Polyclinic University of 
      Messina, Messina, Italy.
FAU - Maio, Raffaele
AU  - Maio R
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Succurro, Elena
AU  - Succurro E
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Hribal, Marta L
AU  - Hribal ML
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Andreozzi, Francesco
AU  - Andreozzi F
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
FAU - Sesti, Giorgio
AU  - Sesti G
AD  - Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, 
      Italy.
FAU - Sciacqua, Angela
AU  - Sciacqua A
AD  - Department of Medical and Surgical Sciences, University Magna Graecia of 
      Catanzaro, Catanzaro, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230706
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Blood Glucose)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2
MH  - Blood Glucose/metabolism
MH  - Glucose Tolerance Test
MH  - Biomarkers
MH  - *Renal Insufficiency, Chronic/diagnosis/complications
PMC - PMC10361654
OTO - NOTNLM
OT  - endocan
OT  - glucose tolerance
OT  - oxidative stress
OT  - platelets activation
OT  - renal function
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/07/24 06:42
MHDA- 2023/07/25 06:43
PMCR- 2023/01/01
CRDT- 2023/07/24 04:51
PHST- 2023/04/15 00:00 [received]
PHST- 2023/06/20 00:00 [accepted]
PHST- 2023/07/25 06:43 [medline]
PHST- 2023/07/24 06:42 [pubmed]
PHST- 2023/07/24 04:51 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1206336 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2023 Jul 6;14:1206336. doi: 
      10.3389/fendo.2023.1206336. eCollection 2023.